[Targeted radionuclide therapy for castration-resistant prostate cancer].

Abstract

Although patients with castration-resistant prostate cancer frequently have metastases to the bone, they have a relatively favorable prognosis. Therefore, it is important to keep or improve the level of patient's quality of life. The use of strontium-89 for the management of the pain from bone metastasis was approved in 2007 in Japan. A new bone-targeting radiopharmaceuticals using radium-223 is also promising, because a randomized trial showed an overall survival advantage of radium-223 in prostate patients with bone metastases. In this review, we summarize the role of targeted radionuclide therapy for castration-resistant prostate cancer, focusing on strontium-89 and radium-223.

• Authors: Katsumasa Nakamura, Saiji Ohga, Tomonari Sasaki, Shingo Baba, Hiroshi Honda
• Journal: Nihon rinsho. Japanese journal of clinical medicine (Nihon Rinsho) Vol. 72 Issue 12 Pg. 2181-5 (Dec 2014) ISSN: 0047-1852 [Print] Japan
• PMID: 25518355 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Radioisotopes
• Radiopharmaceuticals
• Strontium Radioisotopes
• radium Ra 223 dichloride
• Radium

Topics

• Antineoplastic Agents (therapeutic use)
• Bone Neoplasms (radiotherapy, secondary)
• Humans
• Male
• Prostatic Neoplasms, Castration-Resistant (pathology, radiotherapy)
• Radioisotopes (therapeutic use)
• Radiopharmaceuticals (therapeutic use)
• Radium (therapeutic use)
• Strontium Radioisotopes (therapeutic use)